Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $2.24 billion. The enterprise value is $2.66 billion.
| Market Cap | 2.24B |
| Enterprise Value | 2.66B |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, after market close.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 116.21 million shares outstanding. The number of shares has increased by 5.90% in one year.
| Shares Outstanding | 116.21M |
| Shares Change (YoY) | +5.90% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 3.99% |
| Owned by Institutions (%) | 112.76% |
| Float | 102.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.26 |
| PS Ratio | 1.03 |
| Forward PS | 0.83 |
| PB Ratio | 1.82 |
| P/FCF Ratio | 17.15 |
| PEG Ratio | -1.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 49.91, with an EV/FCF ratio of 20.42.
| EV / Earnings | n/a |
| EV / Sales | 1.22 |
| EV / EBITDA | 49.91 |
| EV / EBIT | n/a |
| EV / FCF | 20.42 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.02 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 12.05 |
| Debt / FCF | 4.93 |
| Interest Coverage | -1.49 |
Financial Efficiency
Return on equity (ROE) is -12.10% and return on invested capital (ROIC) is -2.99%.
| Return on Equity (ROE) | -12.10% |
| Return on Assets (ROA) | -5.30% |
| Return on Capital (ROIC) | -2.99% |
| Revenue Per Employee | $462,949 |
| Profits Per Employee | -$30,048 |
| Employee Count | 4,700 |
| Asset Turnover | 0.82 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -20.61M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.00% in the last 52 weeks. The beta is 1.44, so Evolent Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -36.00% |
| 50-Day Moving Average | 23.84 |
| 200-Day Moving Average | 28.35 |
| Relative Strength Index (RSI) | 31.00 |
| Average Volume (20 Days) | 1,864,122 |
Short Selling Information
The latest short interest is 12.38 million, so 10.65% of the outstanding shares have been sold short.
| Short Interest | 12.38M |
| Short Previous Month | 11.19M |
| Short % of Shares Out | 10.65% |
| Short % of Float | 12.06% |
| Short Ratio (days to cover) | 7.69 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.18 billion and -$141.23 million in losses. Loss per share was -$1.26.
| Revenue | 2.18B |
| Gross Profit | 447.36M |
| Operating Income | -55.94M |
| Pretax Income | -117.59M |
| Net Income | -141.23M |
| EBITDA | 53.37M |
| EBIT | -70.28M |
| Loss Per Share | -$1.26 |
Balance Sheet
The company has $216.74 million in cash and $643.07 million in debt, giving a net cash position of -$426.33 million or -$3.67 per share.
| Cash & Cash Equivalents | 216.74M |
| Total Debt | 643.07M |
| Net Cash | -426.33M |
| Net Cash Per Share | -$3.67 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 10.58 |
| Working Capital | 10.22M |
Cash Flow
In the last 12 months, operating cash flow was $155.47 million and capital expenditures -$25.04 million, giving a free cash flow of $130.43 million.
| Operating Cash Flow | 155.47M |
| Capital Expenditures | -25.04M |
| Free Cash Flow | 130.43M |
| FCF Per Share | $1.14 |
Margins
Gross margin is 20.56%, with operating and profit margins of -2.57% and -6.49%.
| Gross Margin | 20.56% |
| Operating Margin | -2.57% |
| Pretax Margin | -5.40% |
| Profit Margin | -6.49% |
| EBITDA Margin | 2.45% |
| EBIT Margin | -3.23% |
| FCF Margin | 5.99% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.90% |
| Shareholder Yield | -5.90% |
| Earnings Yield | -6.31% |
| FCF Yield | 5.83% |
Analyst Forecast
The average price target for Evolent Health is $41.75, which is 116.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.75 |
| Price Target Difference | 116.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 17.83% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 1.3 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.3 |
| Piotroski F-Score | 4 |